We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

110 hedge funds and large institutions have $394M invested in VanEck Pharmaceutical ETF in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 36 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

8% more funds holding

Funds holding: 102 → 110 (+8)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less capital invested

Capital invested by funds: $405M → $394M (-$10.9M)

3% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 36

5.97% less ownership

Funds ownership: 94.91% → 88.94% (-6%)

72% less call options, than puts

Call options by funds: $1.16M | Put options by funds: $4.13M

Holders
110
Holders Change
+8
Holders Change %
+7.84%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
20
Increased
35
Reduced
36
Closed
11
Calls
$1.16M
Puts
$4.13M
Net Calls
-$2.98M
Net Calls Change
-$3.42M

Top Buyers

Rank Fund Capital Flow
1
VV
Verity & Verity
South Carolina
+$7.49M
2
Morgan Stanley
Morgan Stanley
New York
+$6.44M
3
AC
Avestar Capital
New York
+$4.13M
4
IAA
Independent Advisor Alliance
North Carolina
+$3.88M
5
GIA
Gladstone Institutional Advisory
Florida
+$3.68M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$19.7M
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$11.8M
3
AF
Alerus Financial
North Dakota
-$6.73M
4
JP Morgan Chase
JP Morgan Chase
New York
-$3.53M
5
Bank of America
Bank of America
North Carolina
-$3.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
VanEck Associates
101
VanEck Associates
New York
$5K – – –
AIM
102
Anchor Investment Management
South Carolina
$4.72K – – –
CAS
103
Coppell Advisory Solutions
Texas
$4.31K +$78 +1 +2%
DJSG
104
D.J. St. Germain
Massachusetts
$4.07K – – –
TFGT
105
TS Financial Group (TSFG)
Illinois
$4K +$3.92K +50 New
SWA
106
SOA Wealth Advisors
New York
$2.76K – – –
GRP
107
Global Retirement Partners
California
$1.34K +$78 +1 +7%
HIA
108
Harbor Investment Advisory
Maryland
$170 – – –
GFPC
109
Global Financial Private Client
Florida
$81 – – –
HNB
110
Huntington National Bank
Ohio
$78 – – –
Wells Fargo
111
Wells Fargo
California
$60 -$49K -625 -100%
AF
112
Alerus Financial
North Dakota
– -$6.73M -84,214 Closed
SAM
113
Synergy Asset Management
Washington
– -$1.96M -24,583 Closed
Jane Street
114
Jane Street
New York
– -$739K -9,255 Closed
Marshall Wace
115
Marshall Wace
United Kingdom
– -$621K -7,776 Closed
Millennium Management
116
Millennium Management
New York
– -$617K -7,729 Closed
CA
117
Continuum Advisory
Idaho
– -$232K -2,906 Closed
IAIM
118
International Assets Investment Management
Florida
– -$320K -2,723 Closed
CSPIA
119
Cary Street Partners Investment Advisory
Virginia
– -$59.7K -748 Closed
RAM
120
Riggs Asset Management
Pennsylvania
– -$11.1K -139 Closed
YDMI
121
Y.D. More Investments
Israel
– -$9.58K -120 Closed
FWM
122
Focused Wealth Management
New York
– -$1.12K -14 Closed
1 2 3 4
5

PPH Hedge Fund Activity: Q4 2023 in Review

110 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2023, worth a combined $394M — down 2.7% from $405M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new PPH positions and 11 closed out — a net gain of 9 holders — while 35 added to existing stakes and 36 trimmed.

The largest buyer was Verity & Verity, opening a new position worth an estimated $7.49M. The largest seller was Goldman Sachs, cutting an estimated $19.7M.

  • 110 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2023, up from 102 in Q3 2023.
  • Funds reported $394M of VanEck Pharmaceutical ETF stock for Q4 2023, down 2.7% quarter-over-quarter.
  • 20 funds opened new VanEck Pharmaceutical ETF positions in Q4 2023 and 11 closed out, a net change of +9 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q4 2023 was Verity & Verity, an estimated $7.49M added.
  • The largest VanEck Pharmaceutical ETF seller in Q4 2023 was Goldman Sachs, an estimated $19.7M sold.

Based on aggregated 13F filings for Q4 2023.